Search Results
Your search for ,aLl matches 18302 pages
Showing 11551 - 11600ASCO Quality Care 2017: Study Examines Cancer Center Websites’ Information on Breast Cancer Treatment, Outcomes
As an increasing number of patients look to the internet for cancer information, researchers from the University of Alabama found that the websites of many National Cancer Institute (NCI)-designated cancer centers lack sufficient information to help patients with breast cancer understand all their...
ASCO Quality Care 2017: In-House Specialty Pharmacy at Cancer Center Improves Quality of Care, Reduces Medical Errors
An influx of new oral cancer drugs provides patients with a more convenient and less invasive way to take medication, but such treatments are often associated with adherence challenges and medical errors. New research shows that the addition of an in-house specialty pharmacy at a cancer center in...
Effect of Adjuvant Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer
In a study of National Cancer Database data reported in the Journal of Clinical Oncology, Trifiletti et al found that adjuvant chemoradiotherapy was associated with a survival benefit in patients with resected locally advanced head and neck cancer with negative surgical margins and no extracapsular ...
Remembering Stephen K. Carter, MD, and His National and International Impact on Early Drug Development
Stephen K. Carter, MD, a renowned oncologist who held a variety of executive positions in the pharmaceutical industry and played a major role in the research and development of many widely used cancer and AIDS drugs, died on November 14, 2016, after a long battle against multiple systems atrophy....
Effect of Sorafenib and Hepatitis Status in Advanced Hepatocellular Carcinoma
In a meta-analysis reported in the Journal of Clinical Oncology, Jackson et al found that overall survival with sorafenib (Nexavar) in advanced hepatocellular carcinoma was significantly improved vs comparator treatments among patients who were both hepatitis B virus (HBV)-negative and hepatitis C...
Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer
Kathleen N. Moore, MD, of Stephenson Cancer Center, The University of Oklahoma, and colleagues found that mirvetuximab soravtansine (also known as IMGN853)—an antibody-drug conjugate targeting folate receptor alpha (FRα)—is active in FRα-positive platinum-resistant ovarian cancer, according to a...
Rucaparib in Relapsed Platinum-Sensitive High-Grade Ovarian Cancer
In part 1 of the phase II ARIEL2 trial reported in The Lancet Oncology, Elizabeth M. Swisher, MD, of the University of Washington, and colleagues found that the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib was associated with prolonged progression-free survival among patients with...
Assessment of Therapeutic Response by Intrinsic Subtype for HER2-Positive Breast Tumors
In an analysis of outcomes in the North Central Cancer Treatment Group/Alliance N9831 trial reported in the Journal of the National Cancer Institute, Edith A. Perez, MD, of the Mayo Clinic Cancer Center, and colleagues found that patients with tumors scored as HER2-enriched or luminal subtype...
Columbia, NewYork-Presbyterian, and Life Raft Group Form Cancer Research Partnership
Columbia University Medical Center, NewYork-Presbyterian, and the Life Raft Group, a patient advocacy organization specializing in advanced gastrointestinal stromal tumors (GIST), announced that they have entered into a collaborative research project to investigate the efficacy of a novel system...
Expect Questions About Screening and Potential Overdiagnosis
“The big thing that is going to become more and more of an issue, and that you are going to hear a lot more of this year, and in the next several years, is overdiagnosis,” Otis W. Brawley, MD, FACP, Chief Medical Officer of the American Cancer Society, told The ASCO Post in an interview following...
Continued Reduction in Cancer Mortality Requires Increasing Healthy Behaviors and Removing Inequities in Care
Many news reports about the latest cancer statistics released by the American Cancer Society (ACS) have focused on the 25% reduction in cancer mortality since 1991. Several reports quoted ACS Chief Medical Officer Otis W. Brawley, MD, FACP, who said in a statement1 announcing the publication of...
Suresh Ramalingam, MD, Elected to the American Society for Clinical Investigation
Suresh Ramalingam, MD, Deputy Director of Winship Cancer Institute of Emory University and Assistant Dean for Cancer Research at the Emory School of Medicine, has been elected to the American Society for Clinical Investigation. Dr. Ramalingam, who is the Roberto C. Goizueta Distinguished Chair for ...
Results From MONALEESA-2: Are All CDK4/6 Inhibitors Equal?
Hormone receptor–positive breast cancer is the most common subtype of breast cancer, and while endocrine therapy has long been a mainstay of therapy for these patients, treatment resistance ultimately develops. Therefore, better therapeutic approaches are needed. There are some data to suggest...
First-Line Ribociclib Prolongs Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Breast Cancer
As reported by The ASCO Post from the recent European Society for Medical Oncology Conference, first-line treatment with ribociclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), resulted in significantly longer progression-free survival vs placebo in women with hormone...
Clinical Trials Actively Recruiting Patients With Gynecologic Cancers
Phase I Study Title: Phase I Study to Determine the Effects of Mesenchymal Stem Cells Secreting Interferon Beta in Patients With Advanced Ovarian Cancer Study Type: Phase I/interventional/single-group assignment Study Sponsor and Collaborators: MD Anderson Cancer Center Purpose: To find the...
Researchers Use Cardiomyocytes to Create Index of Cardiotoxicity of Tyrosine Kinase Inhibitors
Researchers at the Stanford University School of Medicine used heart muscle cells made from stem cells to rank commonly used chemotherapy drugs based on their likelihood of causing lasting heart damage in patients. Tyrosine kinase inhibitors can be an effective treatment for many types of cancers, ...
University of Pittsburgh Medical Center Joins International Coalition to Improve Cancer Care
A new global initiative that includes founding partner University of Pittsburgh Medical Center was launched on January 17, 2017, at the World Economic Forum’s Annual Meeting in Davos, Switzerland. It signals a dramatic shift in the way international organizations help country and city leaders...
Regorafenib in Second-Line Setting for Hepatocellular Carcinoma: Balancing Benefit With Toxicity
During the past 40 years, hundreds of randomized trials testing treatments for advanced hepatocellular carcinoma have been published.1 Conventional systemic chemotherapy and radiotherapy lack survival advantages for these patients.1,2 In 2007, a phase III trial demonstrated survival benefits for...
Osimertinib Improves Progression-Free Survival vs Platinum/Pemetrexed in EGFR T790M–Positive NSCLC
In the phase III AURA3 trial reported in The New England Journal of Medicine by Tony S. Mok, MD, of the Chinese University of Hong Kong, and colleagues, osimertinib (Tagrisso) significantly improved progression-free survival vs platinum/pemetrexed (Alimta) among patients with epidermal growth...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bangladesh
The ASCO Post is pleased to present this special focus on the worldwide cancer burden. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For the convenience of the reader, each issue will focus on one country from one of the six regions...
American Cancer Society Awards Medal of Honor to Three Cancer Researchers
Three outstanding individuals have been honored with the American Cancer Society Medal of Honor Award. The Medal of Honor is awarded to those who have made the most valuable contributions and impact in saving more lives from cancer through basic research, clinical research, and cancer control....
Radiotherapy vs Temozolomide in Low-Grade Glioma: The Importance of Molecular Classification
The optimal treatment strategy for low-grade glioma has yet to be established, and practice patterns vary in regard to the timing of treatment, as well as the chosen treatment modality. It was against this backdrop, at a time when the benefits of radiation and chemotherapy remained uncertain but ...
Study Finds Children, Parents Overreport Adherence to Leukemia Treatment
New research suggests that young patients with acute lymphocytic leukemia (ALL)—the most common type of pediatric cancer—and their parents are likely to report to their physician that they took more of their anticancer medication than they actually did. The study, published by Landier et al in...
Clinical Trial to Explore Genetic Cancer Test to Offer Safe Thyroid-Preserving Surgery
University of Pittsburgh School of Medicine scientists and doctors are embarking on the first-ever clinical trial to determine whether a genetic test they pioneered could successfully spare patients with nonaggressive thyroid cancer from complete removal of their thyroid. Such thyroid-preserving...
Update on Fertility Outcomes Among Survivors of Childhood Cancer
“Estimates suggest that by the year 2020, there will be over 500,000 adult survivors of childhood cancer in the United States,” Daniel A. Mulrooney, MD, MS, of the Division of Cancer Survivorship, St. Jude Children’s Research Hospital, Memphis, reported at the 10th Oncofertility Conference in...
Preclinical Study of PI3K/mTOR Inhibitors in Uterine Leiomyosarcomas
According to the National Cancer Institute, uterine sarcomas are rare gynecologic malignancies comprising between 2% and 5% of all uterine malignancies. Leiomyosarcomas, which arise from myometrial muscle, account for 30% of all uterine sarcomas. These aggressive, rare cancers are characterized by...
CCF Researcher Spotlight: David M. Waterhouse, MD, MPH
The Conquer Cancer Foundation (CCF) is excited to partner with David M. Waterhouse, MD, MPH, of Oncology Hematology Care in Cincinnati, Ohio, to increase awareness for the Foundation’s Campaign to Conquer Cancer. The Conquer Cancer Foundation was proud to support Dr. Waterhouse with a Young...
Help Your Patients Better Understand Immunotherapy
Patients are hearing about immunotherapy in the news, and many want to know more about this treatment option. Hand your patients the ASCO Answers Understanding Immunotherapy Fact Sheet. It provides an overview on this treatment type, information on the different types of immunotherapy and side...
An Introduction to Recognizing and Managing Professional Burnout
There’s no getting around it: the practice of oncology can be inherently stressful. First, there’s the workload: compared to other medical specialists, oncologists see a larger number of patients and spend more time with them in face-to-face interactions. It’s not unusual for oncologists to work 60 ...
ASCO Collaborates With Health-Care Provider Organizations on Study of Advanced Practice Providers
For the first time, five health-care provider organizations are partnering to conduct a survey to better understand the specific roles and responsibilities that advanced practice providers have on the cancer care team. The survey is a joint effort by ASCO; the Advanced Practitioner Society for...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer is a group dedicated to advancing cancer research by supporting young women researchers early in their careers through the Conquer Cancer Foundation of ASCO Young Investigator Awards. These 1-year grants give promising researchers the boost they need to get started on the...
ASCO Submits Comments on NIH Data-Sharing Request for Information
Earlier this year, ASCO submitted comments to the National Institutes of Health (NIH) in response to a Request for Information on data-sharing and management (NOT-OD-17-015). In the comment letter, ASCO expressed support for the NIH’s efforts to develop a framework and strategies for data-sharing ...
$1.8M Grant to Wenwei Hu, PhD, to Aid Exploration of Role of Chronic Stress in Cancer Development
A 5-year, $1.8 million grant from the National Cancer Institute awarded to Rutgers Cancer Institute of New Jersey resident research member Wenwei Hu, PhD, will support research to further elucidate the mechanisms behind the most frequently mutated gene in human tumors—p53. The aim is to explore...
Phase II Studies Evaluate New Approaches in Richter Transformation
Despite advances in treating chronic lymphocytic leukemia (CLL), the 5% to 10% of patients who develop Richter transformation continue to have poor outcomes. For these patients, median progression-free survival is approximately 6 months, and median overall survival is about 8 months. Phase II...
Exploring the Opportunities and Challenges of Seamless Drug Development
The traditional three-phase clinical trial process for testing new drugs does not necessarily make sense when it comes to targeted therapies, according to many experts, including regulators, academic researchers, industry chief executive officers, and patient advocates alike. Instead of three...
Continuing Education Information
This CE/CME/CU-accredited supplement is jointly provided by: To earn credit/contact hours, you must read all the articles in this supplement and then go to https://education.annenberg.net/IASLC Release date: February 25, 2017 Expiration date: February 25, 2018Annenberg Center for Health...
Southern Surgical Association Annual Meeting: Isolated Limb Infusion for Extremity Sarcoma May Preserve Limbs
Patients with advanced malignant soft-tissue sarcoma of the extremities have typically faced amputation of the afflicted limb as the only treatment option. However, a technique that limits the application of chemotherapy to the cancerous region can preserve limbs in a high percentage of these...
More Patients With Early-Stage Breast Cancer May Be Able to Avoid Chemotherapy in the Future
Women with early-stage breast cancer who had an intermediate risk recurrence score from a 21-gene expression assay had similar outcomes, regardless of whether they received chemotherapy, a new study from The University of Texas MD Anderson Cancer finds. The research, published by Barcenas et al in ...
ASCO-SITC Clinical Immuno-Oncology Symposium: Utility of Biomarkers for Predicting Colorectal Cancer Survival Depends on Tumor Location
A large population-based study suggests that the utility of particular types of tumor-infiltrating lymphocytes (TILs) to predict colorectal cancer survival depends on where the tumor originates in the body. Although prior research has shown an association between high TIL density and longer...
ASCO-SITC Clinical Immuno-Oncology Symposium: Response to Cancer Immunotherapy May Depend on Gut Bacteria
Researchers have found a link between microbes in the gut (the microbiome) and response to immunotherapy. In the study, the ability of patients with advanced melanoma to respond to programmed cell death protein 1 (PD-1) immune checkpoint inhibitors depended on the presence of a diverse microbiome...
Study Finds Cancer Mortality in Hispanics Varies Among Ethnic Groups
Although cancer is a leading cause of death among Hispanics, the burden of cancer mortality within Hispanic groups has not been well quantified. Now, a study by Pinheiro et al comparing the differences among Hispanic populations and cancer incidence has found that cancer mortality varies...
2017 GU Cancers Symposium: Atezolizumab Plus Bevacizumab Shows Potential in Metastatic Renal Cell Carcinoma
Results from the phase II IMmotion150 study that compared atezolizumab (Tecentriq) plus bevacizumab (Avastin) and atezolizumab monotherapy to sunitinib (Sutent) alone in patients with previously untreated, locally advanced or metastatic renal cell carcinoma were presented at the 2017 Genitourinary...
2017 GU Cancers Symposium: Updated Efficacy and Tolerability of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
At the 2017 Genitourinary Cancers Symposium, Powles et al presented updated efficacy and safety data for durvalumab in patients with locally advanced or metastatic urothelial cancer (Abstract 286). Updated results from the phase I/II trial showed an objective response rate of 20.4% in all...
Optimal Time to Assess Response After Chemoradiotherapy in Anal Squamous Cell Carcinoma
In a post hoc analysis of the UK ACT II trial reported in The Lancet Oncology, Glynne-Jones et al found that the best time to assess for complete response to chemoradiotherapy in patients with anal squamous cell carcinoma is at approximately 26 weeks from the start of treatment. In the ACT II...
Exploring the Opportunities and Challenges of Seamless Drug Development
The traditional three-phase clinical trial process for testing new drugs does not necessarily make sense when it comes to targeted therapies, according to many experts, including regulators, academic researchers, industry chief executive officers, and patient advocates alike. Instead of three...
Many Cancer Survivors Find Online and Telephone Communication With Health-Care Professionals Beneficial
Researchers from the School of Health Sciences at the University of Surrey, Guildford, United Kingdom, have completed the first-ever systematic review of cancer survivors’ experience of online and telephone telehealth interventions in cancer care, according to a recent study reported by Anna Cox,...
Three Assays and Several Laboratory-Developed Tests Highly Concordant Across Platforms in PD-L1 Immunohistochemistry Testing for NSCLC
Programmed cell death ligand 1 (PD-L1) expression assessed by immunohistochemistry in formalin-fixed, paraffin-embedded tumor tissues is currently the main predictive biomarker for the benefit of anti–programmed cell death protein 1 (PD-1) and anti–PD-L1 agents in patients with non–small cell lung ...
New Lung Cancer Staging Manual Set to Modify Clinical Practice
A revised tumor classification based on 70,967 evaluable patients with non–small cell lung cancer (NSCLC) and 6,189 patients with small cell lung cancer is now available to lung cancer specialists around the world in the form of the 8th edition of the tumor, node, and metastasis (TNM)...
Efficacy, Toxicity on a Par for Different Classes of Immune Checkpoint Inhibitors
The two main classes of immune checkpoint inhibitors used to treat non–small cell lung cancer (NSCLC) have essentially the same efficacy and toxicity profiles, according to a systematic review and meta-analysis of 23 trials with a total of 5,899 patients.1 Results showed that about one-fifth of...
Durable Responses Reported With Pembrolizumab in Heavily Pretreated Extensive-Stage Small Cell Lung Cancer
The programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda) has shown durable antitumor activity in patients with extensive-stage small cell lung cancer (SCLC) that expresses programmed cell death ligand 1 (PD-L1), according to an update of the KEYNOTE-028 trial.1 “Median overall ...
